Skip to content
BH
Fibrinolytic Enzyme / Serine Protease

Nattokinase

A serine protease from fermented soybeans that degrades fibrin directly — the only common supplement acting on the clotting side of cardiovascular risk rather than the lipid side. Acute human data on fibrinolysis are genuinely interesting; the long-term outcome data are thinner than the marketing, and one rigorous trial came back null.

cardiovascularlongevity
Tier B— Generally safe — moderate evidence
Evidence gradeC — Animal studies / Case reports
BH

Reviewed & fact-checked by

BiohackingHub Research Team

Editorial Research Team · Last updated: August 19, 2026

Verified

What Nattokinase Is

Nattokinase is a serine protease produced by Bacillus subtilis during the fermentation of soybeans into natto. It was identified in 1987 when an extract of natto degraded fibrin in a plate assay — an unusually direct discovery story for a supplement, and the reason its entire identity is built around fibrinolysis, the breakdown of the fibrin mesh that holds clots together.

That mechanism makes it genuinely different from everything else in a cardiovascular stack. Bergamot, berberine, and statins act on lipids. Omega-3 acts on triglycerides and inflammation. Nattokinase acts on the thrombotic limb — the process that turns a ruptured plaque into an occluded artery.

Dosing Is Measured in FU, Not Milligrams

Nattokinase activity is standardised in fibrinolytic units (FU). The common convention is 2,000 FU ≈ 100 mg of standardised powder, and most trials used 2,000–7,000 FU/day. Products listing only milligrams without an FU figure are impossible to compare — treat the FU number as the real label.

Practical range: 2,000 FU (100 mg) once daily, taken away from meals. The high-dose trial that mattered (see below) used 10,800 FU/day and still came back null — more is not the fix.

The Evidence, Honestly

Acute fibrinolysis — the strongest card. A single-dose crossover RCT in healthy men showed enhanced fibrinolytic activity and prolonged clotting parameters over 8 hours, with degradation products rising in blood. The enzyme survives digestion well enough to do something measurable.

Blood pressure — modest but real. An 8-week RCT in pre-hypertensive adults reported systolic reductions of roughly 3–5 mmHg versus placebo. A second RCT replicated the finding in a North American population and additionally reported reductions in von Willebrand factor — small effects, but consistent.

Atherosclerosis progression — the null result that matters. The nattokinase atherothrombotic prevention study (2021) — a rigorous, placebo-controlled trial using high-dose nattokinase (10,800 FU/day) over three years — found no effect on carotid intima-media thickness progression and no meaningful change in cardiovascular risk factors. This is the best long-term trial nattokinase has, and it was negative.

The 1,062-participant lipid study. A 2022 open-label study reported improvements in lipids and carotid plaque with 12 months of nattokinase. It is frequently cited as the strongest evidence — but it had no placebo control, and its lipid claims sit awkwardly against the null RCT above. Treat it as hypothesis-generating, not confirmatory.

The honest summary: nattokinase demonstrably alters fibrinolytic and coagulation markers in humans; whether that translates into fewer cardiovascular events has never been shown, and the one trial designed to test a structural outcome failed to find one.

Safety

The bleeding interaction is the entire safety story. Nattokinase measurably prolongs clotting parameters, which means:

  • Do not combine with warfarin, DOACs, or antiplatelet therapy without explicit physician sign-off.
  • Stop at least two weeks before surgery, together with fish oil and other antiplatelet supplements.
  • Bruising easily or prolonged bleeding from minor cuts is the signal to stop.

Outside anticoagulation contexts, trials up to 12 months reported good tolerability.

Related Research

Stacking Interactions

How Nattokinase interacts with other compounds

+
Synergistic

Complementary, not overlapping: bergamot works on the lipid/ApoB side, nattokinase on fibrinolysis. The pairing covers two independent limbs of cardiovascular risk

!
Caution

Both prolong bleeding time at meaningful doses. The combination is common in cardiovascular stacks — flag it to your prescriber and stop both before surgery

=
Neutral

No mechanistic overlap and no documented interaction; berberine covers the metabolic-lipid axis

=
Neutral

Natto the food is the richest K2 source, but nattokinase supplements are routinely de-vitamin-K'd during purification — check the label if you are on warfarin

Protocols using Nattokinase

Evidence-graded stacks that include this compound

The Advanced Cardiovascular Protocol — ApoB, Lp(a) & Fibrinolysislowering-apob-particle-count-and-thrombotic-risk

Safety Profile — Tier B

Generally safe — moderate evidence

Contraindications

  • ●Anticoagulant or antiplatelet therapy (warfarin, DOACs, clopidogrel, chronic aspirin) without physician oversight
  • ●Bleeding disorders
  • ●Scheduled surgery — stop at least 2 weeks before
  • ●Pregnancy and breastfeeding — no safety data

Side Effects

  • ●Generally well tolerated in trials up to 12 months
  • ●Bruising or prolonged bleeding time at higher doses
  • ●Mild gastrointestinal upset occasionally reported

Drug Interactions

Warfarin, DOACs, antiplatelet drugs — additive bleeding risk; this is the interaction that mattersAntihypertensives — modest additive blood-pressure loweringOther fibrinolytic or high-dose omega-3 supplementation — cumulative effect on bleeding time